<DOC>
	<DOCNO>NCT02620384</DOCNO>
	<brief_summary>The primary objective study determine efficacy metolazone synergistic therapy Lasix patient acute decompensated heart failure . This single center double blind randomize placebo- control pilot study addition 5 mg metolazone per day 2 day compare placebo patient admit acute decompensated heart failure .</brief_summary>
	<brief_title>MELT Heart Failure</brief_title>
	<detailed_description>Heart failure major source morbidity , mortality grow public health cost . In US , number congestive heart failure patient 4 million 550,000 new annually report case . The annual cost heart failure management exceed 35 billion dollar per year.The heart failure readmission average length hospital stay cost approximately $ 11,000 per patient . Loop diuretic use alone majority case promote diuresis . An association increase creatinine increase risk renal dysfunction , cardiorenal syndrome , face high dose loop diuretic raise question regard safety toxicity high dose loop diuretic . While dose diuretic ubiquitous , little data exists guide use many clinician uncertain initiate limit therapy . Prospective randomize data large number decompensated heart failure patient receive metolazone addition standard therapy scarce need definitive evaluation term clinical outcome safety . In many case , `` step approach '' oral loop diuretic advance intravenous finally combination high dose diuretic employ . Primary endpoint : Total urinary output negative fluid balance millilitre ( ml ) 48 hour follow first dose intravenous diuretic . Secondary endpoint : 1 . Change weight admission day 2 . 2 . Degree improvement dyspnea 6,12 , 24,36 , 48 hour assess Modified Borg Scale ( 1-10 ) 3 . All cause mortality 30 day . 4 . Time difference diuretic dose study drug . 5 . Total dose diuretic administer first 48 hour discharge . 6 . Inotrope administration hospital stay . Further exploratory endpoint : 1 . Sodium , creatinine , hemoglobin level admission , 48-hours , discharge . 2 . BNP admission , day 2 , discharge . BNP discharge first 10 patient . 3 . Length hospital stay . 4 . All cause readmission occur within 30 day discharge . 5 . Heart failure readmission occur within 30 day post discharge . Safety endpoint : 1 . Severe electrolyte abnormality require aggressive replacement define potassium level less 3.0 meq/L magnesium level less 1.5 meq/L study . 2 . Severe hypotension follow study drug administration ( MAP le 55 mm Hg ) . This single center study least 200 patient admit Aultman Hospital clinical decompensated congestive heart failure ( NYHA III-IV ) . It double blind randomize placebo- control pilot study addition 5 mg metolazone per day 2 day compare placebo patient admit acute decompensated heart failure . We compare strategy early institution metolazone standard care patient admit decompensated heart failure volume overload . All patient receive standard heart failure therapy , include restrict diuretic , digoxin , angiotensin convert enzyme inhibitor angiotensin II receptor blocker , beta blocker , aldosterone antagonist , hydralazine , and/or nitrate , discretion treat physician . After informed consent obtain , patient randomize 1:1 treatment arm placebo arm . Two additional dos metolazone within 6 24 hour administration standard intravenous diuretic give treatment arm . Patients physician blind administer drug ( metolazone v placebo ) .Drug distribute pharmacy patient consent enrolled trial . Specific guidance/recommendations regard diuretic therapy provide ( documented detail ) discretion treat physician . We collect data demographic , co-morbidities , clinical presentation outcomes metolazone administration patient follow one week ( +3 ) 30 ( ±7 ) day post discharge .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Metolazone</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Age 18 year old Current hospitalization chronic congestive heart failure admission 48 hour prior inclusion . Chronic heart failure define require treatment minimum 30 day prior current admission , NYHA Class III IV time hospitalization , leave ventricular ejection fraction le 40 % within one year evidence heart failure preserve ejection fraction evidence diastolic dysfunction echocardiogram . Admitted clinical decompensated heart failure base history , physical exam , parameter indicate extracellular volume expansion include JVP ≥ 8 cm water 1+ great peripheral edema Is able dosed study medication within six ( 6 ) hour first dose IV diuretic Baseline severe hypotension ( Mean arterial pressure &lt; 55 mm Hg ) Creatinine clearance le 20 ml/min creatinine great 2.5 mg/dl . Serum sodium le 128 meq/L . Serum Potassium &lt; 3.0 meq/L . Known adverse reaction metolazone Inability take oral medication Severe Aortic Stenosis ( AVA &lt; 0.8cm2 ) History Hypertrophic obstructive cardiomyopathy Metastatic Carcinoma per history Severe COPD , FEV &lt; 1L Severe dyspnea require prolonged CPAP , BIPAP intubation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metolazone</keyword>
	<keyword>Heart Failure</keyword>
</DOC>